| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825081 | Clinical Therapeutics | 2014 | 12 Pages |
Abstract
Sucroferric oxyhydroxide is an effective phosphate binder for chronic kidney disease patients receiving hemodialysis and may offer an advantage in terms of pill burden. Gastrointestinal side effects are similar to those of current phosphate binders. Advantages of other phosphate binders (ie, the lipid- and uric acid-lowering abilities of sevelamer) may outweigh the pill burden benefits of sucroferric oxyhydroxide.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Ava (Candidate), Akram MD, FACP, FASN, James MD, Brian PharmD,